Jasper Therapeutics Reports Q3 2025 Financial Results and Corporate Update
On November 10, 2025, Jasper Therapeutics, Inc. (Nasdaq: JSPR), a clinical-stage biotech company developing briquilimab—a novel antibody targeting c-Kit (CD117) to treat mast cell-driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma—released its financial results for the quarter ending September 30, 2025, along with a corporate update.
Focus on Advancing Briquilimab Programs
Ronald Martell, President and CEO of Jasper Therapeutics, stated:
“With a number of data events expected in the coming months, we remain focused on advancing our programs in chronic urticaria and continue to believe that briquilimab has the potential to serve as a highly differentiated therapeutic in mast cell disease based on the results we’ve generated thus far.”
Investigation of Anomalous Efficacy Results
The company is concluding its review of unusual efficacy results from the 240mg Q8W and 240mg/180mg Q8W cohorts in the BEACON study. Jasper is optimistic as the investigation indicates these outcomes are not due to any issues with the drug substance or product.
“We plan to complete the investigation and report final conclusions in the fourth quarter of this year.”
Summary
Jasper Therapeutics continues to make progress in its briquilimab programs, addressing key questions to validate the therapy’s potential in treating mast cell diseases.